Quartzy Secures $23M Funding to Accelerate Life Sciences Procurement Platform

Why It Matters

By streamlining lab purchasing, Quartzy can accelerate scientific discovery and lower operational costs for research institutions, a critical advantage as biotech spending rises. The investment signals strong investor confidence in digital supply‑chain solutions for life sciences.

Key Takeaways

• Quartzy raised $23M from Avenue Capital and BroadOak.
• Platform serves 3,000+ labs with 10M products from 1,000 suppliers.
• Funding will expand software, supplier network, and fulfillment infrastructure.
• Investors see Quartzy as critical life‑science procurement infrastructure.
• Aim to cut lab supply fragmentation and accelerate research timelines.

Pulse Analysis

The life‑science sector is increasingly dependent on digital tools to manage complex supply chains, and procurement platforms are emerging as essential infrastructure. Researchers often face costly delays when reagents or equipment arrive late, prompting venture capital to back solutions that unify ordering, inventory, and logistics. Quartzy’s model—combining a cloud‑based ordering interface with a curated network of suppliers—addresses this friction point, positioning the company alongside other fintech‑style innovators reshaping laboratory operations.

Quartzy’s platform functions as a single pane of glass for lab managers, consolidating purchase requests, approvals, and inventory tracking. With access to over 10 million catalog items from more than 1,000 vendors, the service already supports 3,000+ organizations ranging from academic labs to large biotech firms. By integrating private‑label products and its own fulfillment centers, Quartzy reduces the fragmentation that traditionally plagues research procurement, delivering faster delivery times and more transparent pricing. Early adopters report smoother workflows and fewer experiment interruptions, translating into measurable productivity gains.

The $23 million injection underscores growing investor belief that scalable, software‑driven supply chains will become a competitive moat for life‑science companies. Avenue Capital’s $10 billion asset base and BroadOak’s deep sector expertise provide Quartzy with both capital and strategic guidance to accelerate product development and geographic expansion. As funding fuels enhancements in AI‑driven demand forecasting and deeper API integrations with lab information systems, Quartzy is poised to capture a larger share of the $50 billion global research‑lab spend. The move could set a new benchmark for how scientific institutions source critical materials, ultimately speeding the pipeline from discovery to market.

Deal Summary

Quartzy announced a $23 million funding round backed by Avenue Capital Group and BroadOak Capital Partners to expand its life sciences procurement platform. The capital will be used to enhance its software capabilities, grow its supplier ecosystem, and accelerate go‑to‑market efforts. The round highlights investor confidence in digital infrastructure for research labs.